Attached files
| file | filename |
|---|---|
| EX-2.5 - EX-2.5 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex25_494.htm |
| EX-2.3 - EX-2.3 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex23_496.htm |
| EX-31.2 - EX-31.2 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex312_8.htm |
| EX-2.4 - EX-2.4 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex24_495.htm |
| EX-23.1 - EX-23.1 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex231_6.htm |
| EX-31.1 - EX-31.1 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex311_12.htm |
| EX-21.1 - EX-21.1 - BIOMARIN PHARMACEUTICAL INC | bmrn-ex211_11.htm |
| 10-K - 10-K - BIOMARIN PHARMACEUTICAL INC | bmrn-10k_20151231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of BioMarin Pharmaceutical Inc. (the Company) for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the Report), we, Jean-Jacques Bienaimé, and Daniel Spiegelman, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
/S/ JEAN-JACQUES BIENAIMÉ |
|
|
|
Jean-Jacques Bienaimé |
|
Chief Executive Officer |
|
February 29, 2016 |
|
/S/ DANIEL SPIEGELMAN |
|
|
|
Daniel Spiegelman |
|
Executive Vice President and Chief Financial Officer |
|
February 29, 2016 |